JID: NEUPSY ANTICLE IN PRESS [m6+;September 5, 2018;20:4]

European Neuropsychopharmacology (2018) 000, 1-30





www.elsevier.com/locate/euroneuro

REVIEW

Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan

Barbara Franke^{a,b,*}, Giorgia Michelini^c, Philip Asherson^c, Tobias Banaschewski^d, Andrea Bilbow^{e,f}, Jan K. Buitelaar^g, Bru Cormand^{h,i,j,k}, Stephen V. Faraone^{l,m}, Ylva Ginsberg^{n,o}, Jan Haavik^{m,p}, Jonna Kuntsi^c, Henrik Larsson^{n,o}, Klaus-Peter Lesch^{q,r,s}, J. Antoni Ramos-Quiroga^{t,u,v,w}, János M. Réthelyi^{x,y}, Marta Ribases^{t,u,v}, Andreas Reif^z

E-mail address: Barbara.Franke@radboudumc.nl (B. Franke).

https://doi.org/10.1016/j.euroneuro.2018.08.001 0924-977X/© 2018 Published by Elsevier B.V.

^a Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands

^b Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands

^cKing's College London, Institute of Psychiatry, Psychology & Neuroscience, Social, Genetic & Developmental Psychiatry Centre, London, UK

^dDepartment of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

^e Attention Deficit Disorder Information and Support Service (ADDISS), Edgware, UK

^f ADHD-Europe, Brussels, Belgium

^gRadboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Nijmegen, The Netherlands

^h Department of Genetics, Microbiology and Statistics, Faculty of Biology, Universitat de Barcelona, Barcelona, Catalonia, Spain

¹Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Spain

¹Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Catalonia, Spain

^kInstitut de Recerca Sant Joan de Déu (IR-SJD), Esplugues de Llobregat, Catalonia, Spain

¹Departments of Psychiatry and of Neuroscience and Physiology, State University of New York Upstate Medical University, New York, USA

^mK.G. Jebsen Centre for Neuropsychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

^{*} Corresponding author at: Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

2 B. Franke et al.

- ° Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden
- P Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
- ^qDivision of Molecular Psychiatry, Center of Mental Health, University of Würzburg, Würzburg, Germany
- ^rLaboratory of Psychiatric Neurobiology, Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- ^s Department of Translational Neuroscience, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands
- ^tDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain
- "Psychiatric Genetics Unit, Vall d'Hebron Research Institute (VHIR), Barcelona, Catalonia, Spain
- ^vBiomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Catalonia, Spain
- [™] Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain
- *Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
- $^{
 m y}$ MTA-SE NAP-B Molecular Psychiatry Research Group, Hungarian Academy of Sciences, Budapest, Hungary
- ² Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany

Received 19 November 2017; received in revised form 25 June 2018; accepted 7 August 2018 Available online xxx

KEYWORDS

Developmental trajectory; Treatment; Comorbidity; Cognitive impairment; Genetics; Adult-onset ADHD

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is highly heritable and the most common neurodevelopmental disorder in childhood. In recent decades, it has been appreciated that in a substantial number of cases the disorder does not remit in puberty, but persists into adulthood. Both in childhood and adulthood, ADHD is characterised by substantial comorbidity including substance use, depression, anxiety, and accidents. However, course and symptoms of the disorder and the comorbidities may fluctuate and change over time, and even age of onset in childhood has recently been questioned. Available evidence to date is poor and largely inconsistent with regard to the predictors of persistence versus remittance. Likewise, the development of comorbid disorders cannot be foreseen early on, hampering preventive measures. These facts call for a lifespan perspective on ADHD from childhood to old age. In this selective review, we summarise current knowledge of the long-term course of ADHD, with an emphasis on clinical symptom and cognitive trajectories, treatment effects over the lifespan, and the development of comorbidities. Also, we summarise current knowledge and important unresolved issues on biological factors underlying different ADHD trajectories. We conclude that a severe lack of knowledge on lifespan aspects in ADHD still exists for nearly every aspect reviewed. We encourage large-scale research efforts to overcome those knowledge gaps through appropriately granular longitudinal studies.

© 2018 Published by Elsevier B.V.

1. Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that typically starts during childhood or early adolescence and is thought to follow a trait-like course. The clinical disorder is defined by ageinappropriate levels of inattention and/or hyperactivity-impulsivity interfering with normal development, or functioning, of a person. Although ADHD carries the stigma of being a consequence of modern lifestyle, the first mentioning of the syndrome dates back to the late 18th century (Faraone et al., 2015). Historically, ADHD was described mainly in school-age boys (Still, 2006). Later, it was

recognised that many girls have similar problems - yet often remain unrecognised and, consequently, undiagnosed. During the past decades, it has been demonstrated that ADHD is common in all countries studied (Fayyad et al., 2017; Polanczyk et al., 2014), and that it seriously affects the productivity, life expectancy, and quality of life throughout the lifespan of patients (Erskine et al., 2013). Importantly, it took until the late 20th century before it could convincingly be shown that ADHD also exists in adults, and that continuity exists from childhood to adulthood (Wood et al., 1976) calling for a lifespan perspective on the

Download English Version:

https://daneshyari.com/en/article/11021262

Download Persian Version:

https://daneshyari.com/article/11021262

Daneshyari.com